1. Scrip
  2. >>Business

Gilead And Arcus’ Latest Update Keeps TIGIT Hopes Afloat

Data Readout On 20 December

 
• By Andrew McConaghie

Gilead and Arcus believe their ‘Fc silent’ TIGIT inhibitor candidate could be best in class, but analysts think only outstanding results in lung cancer will sway investor sentiment.

Arcus Biosciences
Arcus and Gilead hope their 'Fc-silent' molecule will have a better safety and efficacy profile than other TIGITs. • Source: Shutterstock

Gilead and Arcus Biosciences have announced a positive new interim readout from their TIGIT inhibitor candidate, domvanalimab, but are holding back the crucial details for now, claiming only that the combination being explored shows “clinically meaningful differentiation” in first-line non-small cell lung cancer compared with PD-1 inhibitor monotherapy.

The announcement on 28 November nevertheless buoyed sentiment around the partners’ candidate, lifting Arcus’s share price more than 7.5% to $28.8 on the NYSE.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip